Introduction
Lung abscess is defined as necrosis of the lung parenchyma, usually caused by microbial infection, often with an air-fluid level.
It may be classified as acute (symptoms < 1month) or chronic (symptoms> 1month).
It may also be classified as primary if it occurs in a previously healthy person or in a person prone to aspiration.
Secondary lung abscess commonly occurs in association with bronchogenic carcinoma or immunodeficiency states e.g. HIV infection.
Lung abscess may be associated with the following
- Pyogenic bacteria
- Tuberculosis
- Fungi
- Parasites
- Pulmonary infarction
- Primary or metastatic malignancies
- Silicosis
- Coal miner’s pneumoconiosis
Clinical features
Symptoms
Symptoms are indolent lasting several weeks. These include:
- Cough, with purulent offensive sputum
- Fever, chills
- Night sweats
- Weight loss
- Pleurtic chest pain
Signs:
- Digital clubbing
- Crepitations
- Pleural friction rub
Differential diagnoses
- Localized bronchiectasis
- Pneumonia
- Tuberculosis
Complications
- Cerebral abscess
- Empyema
- Amyloidosis
Investigations
- Sputum: Gram stain and culture
- Bronchoscopy
- Transthoracic aspiration
- Blood culture
- Chest radiograph
Treatment objectives
- Eradicate bacterial cause
- Drain abscess
- Preserve normal lung function
Non-drug treatment
- Hydration
- Pain relief
- Physiotherapy
Drug treatment
Antibiotics
Metronidazole
Adult:
- 500mg orally every 8hours
Child:
- neonate, initially 15mg/kg orally then 7.5mg/kg every 12 hours;
- 1 month – 12 years: 7.5 mg/kg (maximum 400mg) every 8 hours;
- 12-18years: 400mg every 8hours
Plus:
Amoxicillin
Adult:
- 500mg orally every 8 hours for 7 -10days
Child:
- less than 5 years: a quarter adult dose; 5-10years:
- 5-10 years: half adult dose
Or
Amoxicillin/clavulanic acid
Adult:
- 1g/200mg orally every 8hours for 7-10days (Definitive antibiotic therapy should be based on culture and sensitivity results)
Prevention
- Good dental care
- Adequate treatment of acute pneumonia
- Preventive with vaccination in person at risk
- HIV infected patients who are still capable of responding to a vaccine challenge.
- Patients with recurrent sinopulmonary infection
- Patients with or acquired hypogammaglobulinaemia